His areas of Specialization
The field of gerontology has witnessed significant research findings and great development courtesy of Mikhail Blagosklonny’s passion for working with older persons. Over the years, he has developed an intrinsic urge to do more research on molecular and cell biology. It has since led him to the very depths of understanding the cancer therapeutics and following therapeutic strategies. That notwithstanding, Dr. Mikhail has also risen as a pre-eminent researcher with an acute understanding of tissue-specific cancer therapy and the much sophisticated decelerating organism-based aging. Formerly, he worked as an oncologist at Roswell Park Cancer Institute where his significant efforts in cancer and aging fields.
Working on the TOR Signaling
As a professor, he formulated the hypothesis that regarded the pivotal role of Target of Rapamycin signaling that signifies the behavior of cellular reactions to the availability of energy and nutrients. The development has led to the extension of lives for most cancer patients struggling with chronic levels of cancer. As a passionate advocate of TOR signaling, he has remained a pillar in developing other oncological-based practices. Through this advocacy, he Dr. Mikhail has gained immense recognition with most cancer agencies banking on the rapamycin remedy for lengthening the lives of patients on the verge of dying. To date, his research areas have constituted cancer remedies protecting a patient’s healthy cells from any damage. Nevertheless, he has also developed the keen interest in biogerontology where he specializes in developing anti-aging antidotes protecting the general mechanisms beneath the skin from excessive and undue pressure.
Mikhail Blagosklonny’s Startling Career
About his career, he holds a Masters Degree in Internal Medicine and Doctorate in Cardiology experimental medicine both from Pavlov State University. In the year 200, he became an associate medicine professor at New York Medical College, where he worked until 2002. By October 2002, he was appointed as a senior scientist based in Ordway Research Institute where he worked until April 2009 when he took up a job at Roswell Park Cancer Institute. At the center, he has continued with his sterling performances in this area through his continued advocacies for testing and improvement of cancer screening strategies and means of detection. As a visionary leader in this field, his continued research at the institute has revealed the need for cancer therapies to be tailored in many aspects. One is in a way that it meets the precise mutations existing within a patient’s tumor.
Apart from His Oncological Practice
Apart from his distinguished career as an oncologist, he is also an author of various publications that comprise: research and peer-reviewed articles, books and a columnist for various medical publications. He is credited with founding the Cell Cycle, which he became its founding editor in chief. At Cancer Biology and Therapy, he acts as the Associate Editor specializing in Cell Death and Differentiation. He also significantly contributes to International Journal of Cancer and American Journal of Pathology where he writes about cancer therapy strategies. In his contribution to other associated remedies for old age conditions, he also offers free guidance and counseling for patients whenever he finds time for the same.
AviWeisfogel is a person who trained as a dentist and lives in Old Bridge, New Jersey. He had his own dental practice, Old Bridge Dental Care, since January 1999 and managed it for over 15 years. Dr. AviWeisfogel earned his Bachelor’s Degrees in Biology and Psychology from Rutgers University. He earned his DDS Dentistry degree from the New York University College of Dentistry. Dr. Weisfogel also founded and operates Dental Sleep Masters where he teaches seminars about how to treat sleep disorders with a focus on sleep apnea.
While he had his practice Dr. Weisfogel won Best Dentist from his community in a number of different years. While running his practice he researched how dentists could help people who are suffering from sleep apnea. Sleep apnea serious disorder where people that suffer from it will stop breathing at night, sometimes for extended periods of time. This causes a lack of oxygen to the body and brain which can result in stroke, diabetes, heart disease, and death. It also leads to numerous accidents, especially involving a car, as people who suffer from sleep apnea tend to be drowsy and not as alert as they should be. His goal with Dental Sleep Masters is to help dentists learn how to treat sleep apnea through prescribing oral appliances that the patient can use at night which helps treat this disorder.
In an interview with ideamensch Dr. Weisfogel says he came up with the idea of Dental Sleep Masters through his interest in sleep disorders and realizing that it was a niche in the world of dentistry that wasn’t being fulfilled. He actually wasn’t sorry to leave his dental practice as he eventually discovered it wasn’t something that he was passionate about. He doesn’t regret starting out in dentistry but he is much more fulfilled in spreading the word about how dentists can help with sleep apnea than working as a dentist himself.
To know more visit @: www.yelp.com/biz/weisfogel-avi-dds-old-bridge
Scott Rocklage is the current Managing Partner of 5AM Ventures and is based out of Waltham, MA office. He has years of experience in the healthcare management and is considered to be among the top executives in the industry who have made major contributions to the industry. As he had worked in both public and private healthcare companies in the country, he has the qualifications and the skills that one would need to be in a position that he is today and take the company to new heights.
5AM Ventures is a venture capital company established in 2002. The company offers seed and early stage investment solutions to its portfolio of clients ranging from biopharmaceutical, life sciences, medical technology, biopharma, biotechnology and also research industries. The company was able to secure a fund of $285 million. It previously raised $250 million 2013.
Scott joined 5AM Ventures in 2003 as a Venture Partner and was soon appointed as the Managing Director in 2004. Before joining 5AM Ventures, he was the CEO and Chairman of the Board of Cubist Pharmaceuticals Inc., from 1994 to 2003. He was also the President and Chief Executive Officer of Nycomed Salutar, a diagnostic imaging firm, from 1986 to 1989. During his long career in the healthcare industry, he had also held a number of positions in private pharmaceutical companies like Nycomed and Catalytica, Inc. He is currently the Executive Chairman of Relypsa, Inc, a biopharmaceutical company and the Chief Executive Officer of EPIRUS Biopharmaceuticals, Inc since 2016. He is also the board member of Pulmatrix and Cidara Therapeutics. He serves on the Board of Associates at the Whitehead Institute.
Scott has a strong educational background that made him successful in his career. He earned his BS degree in Chemistry from the University of California, Berkeley. Scott then went on get his Ph.D. in Chemistry from Massachusetts Institute of Technology under the guidance of Nobel Prize winner in Chemistry in 2005, Professor Richard R. Schrock. Over the years, he gained extensive experience and strategic leadership skills which, along with his scientific background, made him a pioneer in the field and a person to look up to in the industry. He is also known for being the co-inventor of about 30 patents and has more than 100 scientific publications to his name.
Scott Rocklage had led numerous teams over the years and raised more than $500 million which includes the one for Cubist Pharmaceuticals initial public offering and many more financing plans. The founders of 5AM Ventures were happy to make Scott a part of their company because of the vast experience that he brings to the company along with him. Scott had also known the founders for over 15 years and was happy to take on the opportunity when he was asked to join them.